• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Systemic treatment selection for patients with advanced pancreatic neuroendocrine tumours (PanNETs)

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    32708210.pdf
    Size:
    2.746Mb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Megdanova-Chipeva, Vera G
    Lamarca, Angela
    Backen, Alison C
    McNamara, Mairead G
    Barriuso, Jorge
    Sergieva, S.
    Gocheva, L.
    Mansoor, Was
    Manoharan, Prakash
    Valle, Juan W
    Affiliation
    Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    Pancreatic neuroendocrine tumours (PanNETs) are rare diseases and a good example of how research is not only feasible, but also of crucial importance in the scenario of rare tumours. Many clinical trials have been performed over the past two decades expanding therapeutic options for patients with advanced PanNETs. Adequate management relies on optimal selection of treatment, which may be challenging for clinicians due to the fact that multiple options of therapy are currently available. A number of therapies already exist, which are supported by data from phase III studies, including somatostatin analogues and targeted therapies (sunitinib and everolimus). In addition, chemotherapy remains an option, with temozolomide and capecitabine being one of the most popular doublets to use. Peptide receptor radionuclide therapy was successfully implemented in patients with well-differentiated gastro-entero-pancreatic neuroendocrine tumours, but with certain questions waiting to be solved for the management of PanNETs. Finally, the role of immunotherapy is still poorly understood. In this review, the data supporting current systemic treatment options for locally advanced or metastatic PanNETs are summarized. Strategies for treatment selection in patients with PanNETs based on patient, disease, or drug characteristics is provided, as well as a summary of current evidence on prognostic and predictive biomarkers. Future perspectives are discussed, focusing on current and forthcoming challenges and unmet needs of patients with these rare tumours. Keywords: PRRT; chemotherapy; neuroendocrine; pancreatic; somatostatin analogues; targeted therapy; treatment.
    Citation
    Megdanova-Chipeva VG, Lamarca A, Backen A, McNamara MG, Barriuso J, Sergieva S, et al. Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). Cancers (Basel). 2020;12(7).
    Journal
    Cancers
    URI
    http://hdl.handle.net/10541/623200
    DOI
    10.3390/cancers12071988
    PubMed ID
    32708210
    Additional Links
    https://dx.doi.org/10.3390/cancers12071988
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.3390/cancers12071988
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?
    • Authors: Rodriguez-Freixinos V, Thawer A, Capdevila J, Ferone D, Singh S
    • Issue date: 2021 May 3
    • Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.
    • Authors: Pozzari M, Maisonneuve P, Spada F, Berruti A, Amoroso V, Cella CA, Laffi A, Pellicori S, Bertani E, Fazio N
    • Issue date: 2018 Dec
    • Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.
    • Authors: Hauser H, Gerson DS, Reidy-Lagunes D, Raj N
    • Issue date: 2019 Nov 27
    • Systemic treatment of neuroendocrine tumors with hepatic metastases.
    • Authors: Demirkan BH, Eriksson B
    • Issue date: 2012
    • Systemic Therapy for Pancreatic Neuroendocrine Tumors.
    • Authors: Lavingia V, Gohel S, Sirohi B
    • Issue date: 2024 May
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.